Rociletinib (CO-1686) USA Expanded Access Program

Summary

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications